Ubs Group Ag Merus N.V. Transaction History
Ubs Group Ag
- $611 Billion
- Q3 2025
A detailed history of Ubs Group Ag transactions in Merus N.V. stock. As of the latest transaction made, Ubs Group Ag holds 581,071 shares of MRUS stock, worth $55.8 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
581,071
Previous 577,694
0.58%
Holding current value
$55.8 Million
Previous $30.4 Million
80.04%
% of portfolio
0.01%
Previous 0.01%
Shares
35 transactions
Others Institutions Holding MRUS
# of Institutions
288Shares Held
64.1MCall Options Held
1.65MPut Options Held
758K-
Paradigm Biocapital Advisors LP New York, NY4.37MShares$420 Million13.26% of portfolio
-
Avoro Capital Advisors LLC New York, NY3.54MShares$340 Million4.56% of portfolio
-
Commodore Capital LP New York, NY3.53MShares$338 Million21.18% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.05MShares$292 Million5.34% of portfolio
-
Hbk Investments L P Dallas, TX2.85MShares$273 Million3.71% of portfolio
About Merus N.V.
- Ticker MRUS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,878,200
- Market Cap $4.4B
- Description
- Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase...